UBI集團訊息

  1. UBI集團訊息

Current Outlook and Future Trends in HIV Treatment Symposium

As a new approach in dealing with the unmet needs in HIV treatment the field of global AIDS therapy has embarked upon using monoclonal antibodies for breakthrough therapy and even functional cure. As development of monoclonal antibody drugs is also a major focus of the Taiwan biotechnology industry, United BioPharma (UBP, 6471) plans to hold a symposium on the current outlook and future trends in HIV treatment on Aug 22nd (Friday) at Grand Hyatt Taipei Hotel. Experts from the United States, China and Taiwan will be invited to share their expertise and research progress.

The speakers to be invited for this symposium include Dr. Daniel R. Kuritzkes, Dr. Mathias D. Lichterfeld and Dr. Jonathan Li from Harvard Medical School; Dr. Tae-Wook Chun from National Institutes of Health; Dr. Flossie Wong-Staal from Center for AIDS Research, UCSD; Dr. Hao Wu from Capital Medical University; Dr. Wing-Wai Wong from Taipei Veterans General Hospital. The latest research progress on AIDS treatments will be presented and discussed at the symposium. The symposium will address topics of the diversity of HIV reservoirs, the prediction of HIV viral rebound factors after HAART interruption in HIV patients, treatment strategies of viral load after HIV infection, strategies for CD4 monoclonal antibody in HIV functional cure and the condition for use of the new long-acting AIDS drug, Albuvirtide, combined with LPV/r in HIV patients. United BioPharma also invites Dr. Yi-Mng (Arthur) Chen, Center for infectious disease and Cancer research, Kaohsiung Medical University, as the Chairperson of the panel discussion at this symposium and Centers for Disease Control, Taiwan Ministry of Health and Welfare as the advisory government institute.

It is expected that this symposium will spark a synergistic interaction between AIDS experts from Taiwan and worldwide institutes.


The information of Current Outlook and Future Trend in HIV Treatment Symposium, please find the below link:
http://www.unitedbiopharma.com/0812/0812Symposium_V4.html

About UBP (6471)
UBP was established in September 2013 as a spinoff from United Biomedical, Inc., Asia, and is strategically partnering with Formosa Plastics Group. UBP has an integrated monoclonal antibody drug development platform, and focuses on development, manufacturing, and marketing of innovative monoclonal antibody drugs and biosimilars. With a spirit of “innovation and practicality,” UBP is dedicated to addressing unmet medical needs, thereby improving the health of mankind and economic advancement of Taiwan. For more information, please visit http://www.unitedbiopharma.com
回上頁